Nutrition 21 to Provide Chromax for Diabetes Study

Nutrition 21 to Provide Chromax for Diabetes Study

PURCHASE, N.Y.Nutrition 21 (www.nutrition21.com) will provide its Chromax chromium picolinate for a studyof chromium picolinates benefits on subjects with metabolic syndrome(Syndrome X), particularly its ability to improve insulin resistance, accordingto the company. The study will also investigate the relationship betweenchromium status and effects on insulin sensitivity; the prevalence of chromiumdeficiency in people with metabolic syndrome; chromium picolinates potentialas an antioxidant and anti-inflammatory agent; and its effects on otherimportant clinical factors, including serum HDL (good) cholesterol,fasting triglycerides, weight/body composition and blood pressure.

The new 20-week study will involve 60 subjects that have beendiagnosed with metabolic syndrome; subjects will be supplemented with 1,000mcg/d of chromium picolinate or matching placebo for 20 weeks.

The study is funded by the Office of Dietary Supplements (ODS)and the National Institute of Diabetes & Digestive & Kidney Diseases,both of which are under the National Institutes of Health.